Inhibitor of nuclear factor kappa B kinase subunit epsilon (IKBKE) upregulates ribonucleotide reductase M2 (RRM2) by activating the RRM2-AKT pathway, thereby promoting the progression of RCC (Liu et al., 2024). Here, IKBKE is linked to renal cell carcinoma.